


Supplementary Figure 6



Supplementary Figure 6: VDZ binding to T_{Reg} and T_{Eff} cells *in vitro* and *in vivo*

(A) Representative gating strategy. T_{Eff} cells were characterised as CD4⁺CD127⁺CD25⁻ cells, T_{Reg} cells as CD4⁺CD127⁻CD25⁺Foxp3⁺ cells. The expression of $\alpha 4\beta 7$ integrin was determined prior to further analysis for free vedolizumab binding sites.

(B) Representative flow cytometry of T_{Reg} and T_{Eff} cells without fluorescently labelled vedolizumab as gating control for detection of free VDZ binding sites.

(C) Representative flow cytometry of T_{Reg} and T_{Eff} cells with free VDZ binding sites from a patient treated with vedolizumab. Stainings from week 2 and week 6 with respective VDZ trough levels indicated.